ANI PHARMACEUTICALS INC

(c) Our directors and executive officers may from time to time enter into plans or other arrangements for the purchase or sale of our common stock that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or may represent a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K).

On September 15, 2025, Meredith Cook, Senior Vice President, General Counsel and Corporate Secretary, adopted a Rule 10b5-1 trading plan. Ms. Cook’s Rule 10b5-1 trading plan provides for a term commencing on January 13, 2026 and ending on December 31, 2026 for the sale of up to 6,000 shares of common stock of the Company.

On September 18, 2025, Krista Davis, Senior Vice President and Chief Human Resources Officer, adopted a Rule 10b5-1 trading plan. Ms. Davis' Rule 10b5-1 trading plan provides for a term commencing on December 18, 2025 and ending on November 4, 2026 and for the sale of up to (i)1,622 shares of the common stock of the Company, (ii) up to 17,541 shares of common stock upon the vesting of certain RSAs, subject to reduction for shares withheld by the Company to satisfy tax withholding obligations and (iii) up to 4,052 shares of common stock upon the vesting of certain PSUs, subject to the satisfaction of certain performance conditions and reduction for shares withheld by the Company to satisfy tax withholding obligations.